ConductScience.org, home

Paper2491964

Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.

Balazsovits JA and 6 others. Cancer Chemother Pharmacol, 1989. Cited by 100 papers, by iCite.

Cite this record

ConductScience Library. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Papers, record 2491964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2491964

Download JSON
Disease
breast cancer1,032 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1989
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
100
iCite
Relative citation ratio, by iCite
3.1
iCite
Revised in PubMed
2019-08-28
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Balazsovits JAJ A
2Mayer LDL D
3Bally MBM B
4Cullis PRP R
5McDonell MM
6Ginsberg RSR S
7Falk RER E

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
HeartMajor topic
LiposomesMajor topic
Animals
DNA
Edema
Female
Hydrogen-Ion Concentration
Irritants
Mast-Cell Sarcoma
Mice
Mice, Inbred DBA

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01367028A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast CancerResults

Source ClinicalTrials.gov

Download CSV of trials

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17127308Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.Cancer Res1982https://conductscience.org/library/papers/7127308PubMed
24005257Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles.Biochim Biophys Acta1985https://conductscience.org/library/papers/4005257PubMed
33964703Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.Biochim Biophys Acta1986https://conductscience.org/library/papers/3964703PubMed
43967247Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.Cancer Res1985https://conductscience.org/library/papers/3967247PubMed
56883331Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers.Cancer Res1983https://conductscience.org/library/papers/6883331PubMed
67370991Liposomal protection of adriamycin-induced cardiotoxicity in mice.Cancer Res1980https://conductscience.org/library/papers/7370991PubMed
73941333Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer.J Clin Oncol1986https://conductscience.org/library/papers/3941333PubMed
87034780Liposome disposition in vivo. III. Dose and vesicle-size effects.Biochim Biophys Acta1981https://conductscience.org/library/papers/7034780PubMed
923008845Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential.Biochim Biophys Acta1985https://conductscience.org/library/papers/23008845PubMed
106848178Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes.Cancer Res1983https://conductscience.org/library/papers/6848178PubMed
113742676Techniques for encapsulating bioactive agents into liposomes.Chem Phys Lipids1986https://conductscience.org/library/papers/3742676PubMed
126850663Attenuation of dermal toxicity of doxorubicin by liposome encapsulation.Cancer Treat Rep1983https://conductscience.org/library/papers/6850663PubMed
137057359Liposome disposition in vivo II: Dose dependency.J Pharm Sci1982https://conductscience.org/library/papers/7057359PubMed
146459710Tissue distribution and antitumor effect of liposome-entrapped doxorubicin (adriamycin) in Ehrlich solid tumor-bearing mouse.Acta Med Okayama1981https://conductscience.org/library/papers/6459710PubMed
156897042Is half-life of circulating liposomes determined by changes in their permeability?FEBS Lett1982https://conductscience.org/library/papers/6897042PubMed
167201392Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes.Eur J Cancer Clin Oncol1982https://conductscience.org/library/papers/7201392PubMed

Download CSV of references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.

PMIDTitleJournalYearIn PapersSource
39861690Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.Pharmaceutics2024https://conductscience.org/library/papers/39861690PubMed
36572154Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy.J Control Release2023https://conductscience.org/library/papers/36572154PubMed
36015347Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs.Pharmaceutics2022https://conductscience.org/library/papers/36015347PubMed
35957103Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy.Nanomaterials (Basel)2022https://conductscience.org/library/papers/35957103PubMed
35057002Development of Pharmaceutical Nanomedicines: From the Bench to the Market.Pharmaceutics2022https://conductscience.org/library/papers/35057002PubMed
33921088Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines.Int J Mol Sci2021https://conductscience.org/library/papers/33921088PubMed
33449342Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities.Drug Deliv Transl Res2021https://conductscience.org/library/papers/33449342PubMed
31209826Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin.Drug Deliv Transl Res2019https://conductscience.org/library/papers/31209826PubMed
31161432Fibrin Gels Entrapment of a Poly-Cyclodextrin Nanocarrier as a Doxorubicin Delivery System in an Orthotopic Model of Neuroblastoma: Evaluation of In Vitro Activity and In Vivo Toxicity.Pharm Res2019https://conductscience.org/library/papers/31161432PubMed
30884782What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.Pharmaceutics2019https://conductscience.org/library/papers/30884782PubMed
29459867The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Front Immunol2018https://conductscience.org/library/papers/29459867PubMed
29353083Combining ultrasound and intratumoral administration of doxorubicin-loaded microspheres to enhance tumor cell killing.Int J Pharm2018https://conductscience.org/library/papers/29353083PubMed
28839175Oxygen nanobubbles revert hypoxia by methylation programming.Sci Rep2017https://conductscience.org/library/papers/28839175PubMed
28346375Liposomal Formulations in Clinical Use: An Updated Review.Pharmaceutics2017https://conductscience.org/library/papers/28346375PubMed
27155765Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.J Pharm Sci2016https://conductscience.org/library/papers/27155765PubMed
25514405Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages.Int J Mol Sci2014https://conductscience.org/library/papers/25514405PubMed
25316273Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs.Curr Drug Targets2015https://conductscience.org/library/papers/25316273PubMed
23210520Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis.Exp Hematol Oncol2012https://conductscience.org/library/papers/23210520PubMed
18203425Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.Int J Nanomedicine2007https://conductscience.org/library/papers/18203425PubMed
11523222Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer.J Tongji Med Univ2001https://conductscience.org/library/papers/11523222PubMed

See all 35 cited byDownload CSV of cited by

Drugs4

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
BEVACIZUMABCHEMBL1201583Results1https://conductscience.org/library/drugs/CHEMBL1201583ChEMBL
TRASTUZUMABCHEMBL1201585Results1https://conductscience.org/library/drugs/CHEMBL1201585ChEMBL
DOCETAXELCHEMBL3545252Results1https://conductscience.org/library/drugs/CHEMBL3545252ChEMBL
DOXORUBICINCHEMBL53463Results1https://conductscience.org/library/drugs/CHEMBL53463ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2491964

GET https://conductscience.org/api/papers/v1/2491964/cited_by?page=2